

11:39 01 Nov 2018

ShareRoot's MediaConsent platform to be utilised in clinical setting for brain research

ShareRoot Ltd (ASX:SRO) will utilise its MediaConsent platform in a collaborative effort to optimise research into brain diseases, injuries and disorders.

Neuroscience Trials Australia (NTA) is the second Australian research collaborator to join a major project to trial MediaConsent in a clinical research setting.

This is being done with a view to enhance the experience for patients and carers in their treatment journey and clinical researchers in their research discovery and development goals.

The work aims to improve the dynamics of clinical trial recruitment, patient engagement and understanding of patients' health-related behaviour through social media and accompanying consent processes.

ShareRoot CEO Noah Abelson-Gertler said, "With the MediaConsent platform, we will enable patients to participate in clinical research in a whole new way."

NTA has joined the project led by ShareRoot's The Social Science (TSS), a Melbourne-based digital agency which was acquired by ShareRoot in April 2018.

READ: ShareRoot's MediaConsent platform to enhance clinical research at St Vincent's Hospital Melbourne

In October, St Vincent's Hospital in Melbourne signed onto the project led by TSS managing director Michelle Gallaher.

NTA is a leading Australian based, not-for-profit contract research organisation specialising in neuroscience clinical research.

It is a business unit within the Florey Institute of Neuroscience and Mental Health, the largest brain research institute in the southern hemisphere.

READ: ShareRoot eyes growth opportunities as data privacy regulations become stricter

Abelson-Gertler said, "Neuroscience Trials Australia offers us a wealth of knowledge and opportunity to shape the SaaS platform to deliver equal value for researchers and patients with neurological diseases, disorders, and injuries, whilst protecting patient data and privacy."

Price: 0.185

Market Cap: \$6.83 m

1 Year Share Price Graph



March 2020 September 2020 March 2021

Share Information

Code: OPL

Listing: ASX

52 week	High	Low
	0.34	0.04


Sector: Online business & e-commerce

Website: opyl.ai

Company Synopsis:

Opyl (ASX:OPL) is a new generation company working at the intersection of artificial intelligence, social media and clinical trials.

action@proactiveinvestors.com.au



NTA has long recognised the value of social media in raising awareness about the value and process of clinical trials and has worked with TSS for two years.

This relationship has built capabilities and a global digital footprint enhancing the organisation's ability to undertake new clinical trials in Australia, build digital capabilities within the clinical trial team, and attract volunteers and physicians to participate in trials.

Social media a "business-critical tool"

NTA CEO Tina Soulis said, "Social media is fast becoming a business-critical tool in clinical research, in helping us communicate with the public, letting them know about trial opportunities and recruiting volunteers and physicians to participate in new treatments.

"We're excited to collaborate on this new and innovative approach to accessing real-world data, opening up a new world of compliant and ethically sourced data and insights for our researchers."

READ: ShareRoot to integrate secure login technology with its MediaConsent platform

The shared goal with the MediaConsent clinical collaboration is to demonstrate how ShareRoot's technology can protect patient data and privacy on social media whilst supporting the advancement of clinical research within a secure and compliant platform.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Opyl Ltd named herein, including the promotion by the Company of Opyl Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).